% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Koch:272843,
      author       = {J. Koch and J. Beil$^*$ and S. Berchtold and D. Mönch and
                      A. Maaß and I. Smirnow and A. Schenk and M. E. Carter and
                      L. D. Kloker and T. Leibold and P. Renner and M.-H. Dahlke
                      and U. M. Lauer$^*$},
      title        = {{E}stablishing a {N}ew {P}latform to {I}nvestigate the
                      {E}fficacy of {O}ncolytic {V}irotherapy in a {H}uman {E}x
                      {V}ivo {P}eritoneal {C}arcinomatosis {M}odel.},
      journal      = {Viruses},
      volume       = {15},
      number       = {2},
      issn         = {1999-4915},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2023-00416},
      pages        = {363},
      year         = {2023},
      abstract     = {Oncolytic virotherapy constitutes a promising treatment
                      option for many solid cancers, including peritoneal
                      carcinomatosis (PC), which still represents a terminal stage
                      of many types of tumors. To date, the in vitro efficacy of
                      oncolytic viruses is mostly tested in 2D-cultured tumor cell
                      lines due to the lack of realistic 3D in vitro tumor models.
                      We have investigated the feasibility of virotherapy as a
                      treatment option for PC in a human ex vivo peritoneum
                      co-culture model. Human HT-29 cancer cells stably expressing
                      marker genes GFP and firefly luciferase (GFP/luc) were
                      cultured on human peritoneum and infected with two
                      prototypic oncolytic viruses (GLV-0b347 and MeV-DsRed). Both
                      viral constructs were able to infect HT-29 cells in
                      patient-derived peritoneum with high tumor specificity. Over
                      time, both GFP signal and luciferase activity decreased
                      substantially, thereby indicating successful virus-induced
                      oncolysis. Furthermore, immunohistochemistry stainings
                      showed specific virotherapeutic infections of HT-29 cells
                      and effective tumor cell lysis in infected co-cultures.
                      Thus, the PC model established here provides a clinically
                      relevant screening platform to evaluate the therapeutic
                      efficacy of virotherapeutic compounds and also to
                      investigate, in an autologous setting, the immunostimulatory
                      potential of oncolytic viruses for PC in a unique human
                      model system superior to standard 2D in vitro models.},
      keywords     = {ex vivo peritoneal culture model (Other) / oncolytic
                      measles vaccine virus (Other) / oncolytic vaccinia virus
                      (Other) / peritoneal carcinomatosis (Other) / virotherapy
                      (Other)},
      cin          = {TU01},
      ddc          = {050},
      cid          = {I:(DE-He78)TU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36851574},
      doi          = {10.3390/v15020363},
      url          = {https://inrepo02.dkfz.de/record/272843},
}